Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer.
Slightly overvalued with limited growth.
Share Price & News
How has Agenus's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: AGEN's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: AGEN exceeded the US Biotechs industry which returned 27% over the past year.
Return vs Market: AGEN exceeded the US Market which returned 15.4% over the past year.
Price Volatility Vs. Market
How volatile is Agenus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StAgenus Inc. (NASDAQ:AGEN) Shares Could Be 41% Below Their Intrinsic Value Estimate
1 month ago | Simply Wall StDid You Manage To Avoid Agenus' (NASDAQ:AGEN) Painful 58% Share Price Drop?
4 months ago | Simply Wall StAgenus Inc. Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Is Agenus undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: AGEN ($3.31) is trading below our estimate of fair value ($6.15)
Significantly Below Fair Value: AGEN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: AGEN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AGEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AGEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AGEN has negative assets, so we can't compare its PB Ratio to the US Biotechs industry average.
How is Agenus forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AGEN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AGEN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AGEN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AGEN's revenue (40.8% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: AGEN's revenue (40.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AGEN's Return on Equity is forecast to be high in 3 years time
How has Agenus performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AGEN is currently unprofitable.
Growing Profit Margin: AGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AGEN is unprofitable, and losses have increased over the past 5 years at a rate of 8% per year.
Accelerating Growth: Unable to compare AGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.3%).
Return on Equity
High ROE: AGEN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is Agenus's financial position?
Financial Position Analysis
Short Term Liabilities: AGEN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: AGEN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: AGEN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: AGEN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AGEN has sufficient cash runway for 8 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: AGEN is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.
What is Agenus's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Garo Armen (67 yo)
Dr. Garo H. Armen, Ph.D., founded Agenus Inc. in 1994 and has been its Chief Executive Officer since 1994. Dr. Armen serves as an Executive Chairman of Agenus Inc. He has been an Executive Director of Agen ...
CEO Compensation Analysis
Compensation vs Market: Garo's total compensation ($USD9.94M) is above average for companies of similar size in the US market ($USD2.06M).
Compensation vs Earnings: Garo's compensation has increased whilst the company is unprofitable.
|President & COO||0.58yr||US$2.39m||0.021% |
|VP, Chief Compliance Officer||2.08yrs||US$1.61m||0.0075% |
|VP of Finance||1yr||US$497.48k||no data|
|VP of Investor Relations & Communications||no data||no data||no data|
|Chief Commercial Officer & Head of HR||3.08yrs||US$461.73k||no data|
|Head of Translational Medicine & Bioinformatics||2.58yrs||no data||no data|
|Global Head of Clinical Operations||1.42yrs||no data||no data|
|Scientific Director & Head of Drug Discovery||no data||no data||no data|
|VP & Head of Commercial||1.08yrs||no data||no data|
|Vice President of Cellular Immunology||no data||no data||no data|
|Vice President of Business Development & Alliance Management||2.58yrs||no data||no data|
Experienced Management: AGEN's management team is considered experienced (2.1 years average tenure).
|Independent Director||4.25yrs||US$559.92k||0.048% |
|Independent Director||17.42yrs||US$457.14k||no data|
|Independent Lead Director||11.58yrs||US$562.14k||0.031% |
|Independent Director||13.42yrs||US$662.14k||0.041% |
Experienced Board: AGEN's board of directors are seasoned and experienced ( 11.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.7%.
Agenus Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Agenus Inc.
- Ticker: AGEN
- Exchange: NasdaqCM
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$567.392m
- Shares outstanding: 171.42m
- Website: https://agenusbio.com
Number of Employees
- Agenus Inc.
- 3 Forbes Road
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AGEN||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Feb 2000|
|AJ81||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Feb 2000|
Agenus Inc., a clinical-stage immuno-oncology company, engages in advancing a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer. The company ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/08/07 00:25|
|End of Day Share Price||2020/08/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.